Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
QuantumCyte
AddedFeb 16, 2024
UpdatedJun 18, 2026
QuantumCyte

QuantumCyte

Series A

QuantumCyte: Innovating cancer drug assays with automated tissue dissection and ROI isolation technology.

HQ
Sunnyvale, CA, US
Founded
2013
Overview
Compare
Fundraising
Employees
Website

QuantumCyte, founded with a mission to revolutionize cancer drug assays, focuses on developing advanced technology for isolating complex regions of interest (ROIs) from FFPE tissue slides. Their core product, an automated tissue dissection system, utilizes digital tissue maps to precisely isolate ROIs containing informative biomarkers. This innovation aims to enhance the accuracy and efficiency of cancer research and drug development, targeting the oncology market and research institutions.

Notable figures associated with QuantumCyte include experts in oncology and biomedical engineering, though specific names are not provided. The company has achieved significant milestones, such as the development and implementation of their QCPRECISE! Platform, which has been featured in various scientific posters and publications. QuantumCyte's impact is evident in its contribution to more precise and informative cancer drug assays, potentially accelerating the discovery of effective cancer treatments.

QuantumCyte - Similar Companies

QTC Care logo

QTC Care

qtclinics.com

RareCyte logo

RareCyte

rarecyte.com

QuantumBio logo

QuantumBio

quantumbioinc.com

ClearLight Biotechnologies logo

ClearLight Biotechnologies

Aquyre Biosciences logo

Aquyre Biosciences

lltech.co

Quantgene logo

Quantgene

quantgene.com

Quantum Diamond Technologies logo

Quantum Diamond Technologies

BloodQ logo

BloodQ

bloodq.com

Techcyte logo

Techcyte

techcyte.com

On-Q-ity logo

On-Q-ity

Ultivue logo

Ultivue

ultivue.com

Quantaras logo

Quantaras

quantaras.com

Quantum Immunologics logo

Quantum Immunologics

CytoTronics logo

CytoTronics

cytotronics.com

OmniCyte logo

OmniCyte

omnicyte.com

QuantumCyte - Quick Facts

Who are QuantumCyte's competitors?

Companies similar to QuantumCyte include QTC Care, RareCyte, QuantumBio and ClearLight Biotechnologies.

When was QuantumCyte founded?

QuantumCyte was founded in 2013.

Where is QuantumCyte's headquarters located?

QuantumCyte's headquarters is located in Sunnyvale, CA, US.

When was QuantumCyte's last funding round?

QuantumCyte's most recent funding round was for $1.1M (USD) in August 2023.

How much has QuantumCyte raised to-date?

As of Aug 15, 2023, QuantumCyte has raised a total of $1.1M (USD).

How many employees does QuantumCyte have?

QuantumCyte has 12 employees as of Feb 5, 2024.

QuantumCyte - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Automation
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Tissue Dissection
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software